Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First in human study of BAY2927088 in advanced NSCLC with EGFR and/or HER2 mutations
2023-503795-24-00Phase 2Authorised
- Sponsor
- Bayer
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, single-arm trial of sevabertinib in non-small cell lung cancer (NSCLC), sponsored by Bayer. Planned start Sep 2022; status: authorised.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503795-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503795-24-00.